BIONET Corp. (TPEX:1784)

Market Cap	3.94B
Revenue (ttm)	1.23B
Net Income (ttm)	71.15M
Shares Out	50.61M
EPS (ttm)	1.40
PE Ratio	55.56
Forward PE	n/a
Dividend	1.41 (1.81%)
Ex-Dividend Date	Oct 3, 2025

Volume	120,928
Average Volume	304,555
Open	78.30
Previous Close	77.90
Day's Range	77.00 - 78.30
52-Week Range	62.40 - 113.00
Beta	0.45
RSI	56.95
Earnings Date	Aug 11, 2025

About BIONET

BIONET Corp. provides cell therapy services in Taiwan and internationally. The company offers stem cell banking services, including stem cell storage, mesenchymal stem cell storage, dental stem cell storage, adipose stem cell, and peripheral blood stem cells and immune cells; and genetic testing services. It also provides stem anti-aging and ANIKINE series products; and Exosome, a novel cell-free therapy. In addition, the company offers regenerative medicine, analytical testing, clinical and preclinical research, and commercialized cell-derived...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1989
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 1784

Financial Performance

In 2024, BIONET's revenue was 1.22 billion, an increase of 8.40% compared to the previous year's 1.13 billion. Earnings were 83.70 million, an increase of 6.76%.